Latest 17-Hydroxyprogesterone caproate Stories
-AMAG Closes $340 Million Term Loan WALTHAM, Mass., Nov. 12, 2014 /PRNewswire/ -- AMAG Pharmaceuticals, Inc.
McGuff Pharmaceuticals, Inc.
In a study to be presented on February 14 between 8 a.m. and 10 a.m. PST, at the Society for Maternal-Fetal Medicine's 33rd annual meeting, The Pregnancy Meeting ™, researchers will report findings that suggest that 17P, a form of progesterone, is not effective in preventing preterm birth among women with twin pregnancies — and may possibly be harmful.
In a study to be presented today at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting ™, in Dallas, Texas, researchers will report findings that indicate that duration of stay in the United States is associated with increased risk of preterm birth for Hispanic women.
- totally perplexed and mixed up.